Alchemia banks on 2010
By Dylan Bushell-Embling
Thursday, 02 October, 2008
Thursday, 02 October, 2008
Alchemia [ASX: ACL] has recorded an $11 million loss for the financial year but reports a healthy cash reserve of $15.3 million.
Equity increased from around $87 million to $102 million.
The company expects to go into profit in 2010. Its generic fondaparinux, a copy of GSK’s Arixta, for venous thromboembolism, is scheduled for market launch in the US next year through its partner Dr Reddy’s.
Related News
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
